Welcome to the 565th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.
The highlight of this week's edition is the long-term outcomes from the REST randomised trial. There are also guidelines on maternal cardiac arrest & treatment of acute pain in children; narrative reviews on acute meningitis & heart failure after right ventricular myocardial infarction; editorials on acute respiratory distress syndrome & understanding statistical power; and commentaries on traumatic brain injury & frailty in intensive care medicine; as well as correspondence on PEEP & defining right ventricular dysfunction in critical illness.
If you only have time to read one review article this week, try this one on extracorporeal membrane oxygenation in COVID-19 associated acute respiratory distress syndrome.
We're delighted to announce our next livestream will be the results presentation of the PILOT trial, a 2,250-patient cluster-randomized cluster-crossover trial comparing a lower SpO2 target (90%; range 88-92%), an intermediate SpO2 target (94%; range 92-96%), and a higher SpO2 target (98%; range 96-100%) with regard to the outcome of days alive and free of invasive mechanical ventilation. As usual, this will be a full, free livestream including results, independent editorial, viewers questions and expert panel discussion. It is scheduled to start at 20:00 UTC+1. More details will follow over the coming days.
Registration for the Critical Care Reviews Meeting 2023 opens on Monday October 17th at 7pm UTC+1. If you are interested in the latest major trials in critical care, this is the meeting for you. CCR22 attracted in-person delegates from 26 countries, so if you want to attend this small niche event, it's best to book early. For those who can't attend in-person, we will livestream the entire conference for free, to ensure equity of access to the latest scientific advances in our field. However, nothing quite beats the anticipation of being in Titanic Belfast to hear the results of the latest landmark trials presented for the first time and discussed in depth by an expert panel and audience.
You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.
I hope you find this newsletter useful.
Until next week